EMVision

EMVision operates at the intersection of portable medical imaging, stroke diagnostics, and point-of-care neurotechnology. Its core differentiation is a portable electromagnetic scanner intended to produce bedside or pre-hospital brain imaging without ionising radiation, special shielding, or the physical footprint of CT and MRI systems. The emu™ Brain Scanner and First Responder Brain Scanner concepts target ambulances, aeromedical transport, hospitals, and other locations where rapid triage could affect treatment timing. The company’s ASX listing since 2018 and A$15.9 million of cumulative funding represented in its structured financial profile give it a more mature financing history than a newly formed research spinout, although it remains at a validation-heavy stage rather than a scaled commercial-device stage. The available comparison set does not identify named direct competitors, so a precise peer ranking is not possible. EMVision’s competitive test is likely to be clinical accuracy, workflow integration, regulatory progress, and usability against established CT and MRI infrastructure as well as other portable neuroimaging approaches. Its emphasis on dielectric-property mapping, low-power radio waves, and AI-assisted reconstruction creates a distinct technical position, but clinical adoption evidence and commercial deployment metrics are still limited.

EMVision’s trajectory shows a progression from research-led development toward clinical validation and deployment in constrained-care environments. The company was founded in 2017 and became publicly listed on ASX:EMV in December 2018, raising approximately US$4.3 million at the IPO. Subsequent support included Australian Government grants of approximately US$1.28 million in 2022 and US$1.18 million in 2023, followed by a US$9.92 million post-IPO equity round led by Keysight Technologies on Feb 28, 2024. A further A$5 million grant in July 2025 and A$400,000 grant in May 2026 extended non-dilutive support. Product development also advanced from the general emu™ Brain Scanner toward a backpack-sized device and first-responder applications, highlighted in July 2024. Trial execution became a central inflection point in 2025, when site activations were nearing completion, and in July 2026, when the company prepared to add acute ischemia detection to its validation endpoint. The appointment of Karl Pechmann as CFO adds financial leadership during this transition. Employee-count data remains broad and indicates 11–50 employees, so operating scale cannot be estimated precisely. Commercial revenue, regulatory milestones, and confirmed deployment volumes remain undisclosed.